PatientsHCP
This site is for US Health Care Professionals only.
Dear Doctor header featuring Kamryn, a real patient

Hear what your patients want you to know about living with RMS—and how self-administration helps give them a sense of control and independence

Watch real-patient Kamryn’s story of empowerment, inspired by her neurologist
KESIMPTA® (ofatumumab) is the first and only self-administered B-cell treatment for RMS1-3

Up to date on the efficacy of KESIMPTA?

See the pivotal-trial and long-term study data

Not just an autoinjector pen—a sense of control via self-administration

Dive into dosing and administration

Life with RMS can be complicated. Starting treatment shouldn’t be

Find local coverage and start today with samples*
Kamryn, a real patient, talking to a doctor.

Kamryn R.

Mom, Entrepreneur

Started KESIMPTA first line in 2023

"KESIMPTA gives me back something that I can control, which is taking my medication myself. This plays a role in my sense of independence. Without that, I would have felt a lot more hopeless."

Do you have patients like Kamryn?

You can start them on KESIMPTA today

See how
RMS, relapsing multiple sclerosis.
*Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA and is intended to give patients a chance to see if KESIMPTA may be right for them. 
References: 1. Kesimpta. Prescribing information. Novartis Pharmaceuticals Corp. 2. National Multiple Sclerosis Society. Injectable therapies. 2025. Accessed January 29, 2025. https://www.nationalmssociety.org/article/injectable-therapies 3. Ocrevus Zunovo. Prescribing information. Genentech, Inc.